Nuvalent is a precision oncology biopharmaceutical company that designs and develops targeted therapies specifically focused on treating various forms of advanced cancer, most notably non-small cell lung cancer (NSCLC). Its pipeline candidates are engineered to overcome treatment resistance, address central nervous system metastases, and target specific genomic alterations such as ROS1, ALK, and HER2 mutations driving tumor progression in oncology patients.